Evidence‑Based Management of Allergic Rhinitis in Children

First‑Line Pharmacotherapy

Intranasal corticosteroids are the most effective first‑line therapy for children with allergic rhinitis, outperforming oral antihistamines and leukotriene receptor antagonists in controlling nasal symptoms. Level A evidence. 1
Initiate intranasal corticosteroid monotherapy in children with moderate‑to‑severe symptoms; it provides superior control of sneezing, itching, rhinorrhea, and congestion compared with any other single medication. High‑quality randomized trials. 2

Use second‑generation oral antihistamines (e.g., cetirizine, loratadine, fexofenadine) for intermittent or mild symptoms when intranasal steroids are not tolerated. Evidence from comparative studies. 3
First‑generation antihistamines (e.g., diphenhydramine, chlorpheniramine) should be avoided in children because of sedation, anticholinergic effects, and increased accident risk. Consistent safety data. 3
Intranasal antihistamine azelastine (approved ≥ 5 years) is equal or superior to oral antihistamines for seasonal allergic rhinitis and uniquely improves nasal congestion. Randomized comparative trials. 3

Adding intranasal azelastine to an intranasal corticosteroid yields greater symptom reduction than either agent alone in children with moderate‑to‑severe disease. High‑quality trial evidence. 4
Routine addition of an oral antihistamine to an intranasal corticosteroid does not provide extra benefit; multiple high‑quality trials show no improvement. Level A evidence. 4

Leukotriene receptor antagonists (e.g., montelukast) are inferior to intranasal corticosteroids and should not be used as primary therapy. Comparative effectiveness data. 4
Oral decongestants (pseudoephedrine, phenylephrine) should be avoided in young children due to irritability, insomnia, appetite loss, and cardiovascular concerns. Safety warnings. 3
Topical nasal decongestants (oxymetazoline) must be limited to ≤ 3 days to prevent rebound congestion (rhinitis medicamentosa). Clinical guideline. 2

Identify allergen triggers with skin testing or specific IgE to guide targeted avoidance strategies. Diagnostic recommendation. 1
Implement allergen avoidance: dust‑mite control (humidity reduction, encasements, HEPA vacuuming), complete avoidance of animal allergens, and limit outdoor exposure during high pollen counts. Evidence‑based environmental control. 3

Refer children whose symptoms remain uncontrolled despite optimal pharmacotherapy and environmental measures for allergen immunotherapy (subcutaneous or sublingual). Strong recommendation. 5
Immunotherapy is the only disease‑modifying treatment and may prevent new sensitizations and reduce future asthma risk. Long‑term outcome data. 6
Sublingual immunotherapy is effective for children with asthma and allergic rhinitis, especially for house‑dust‑mite and grass pollen allergens. Trial evidence. 5

Screen for asthma (perform pulmonary function testing if suspected); treating rhinitis can improve asthma control. Clinical correlation. 3
Assess for chronic rhinosinusitis, obstructive sleep apnea, and allergic conjunctivitis in children with persistent rhinitis symptoms. Guideline recommendation. 3

Do not prescribe a combination of intranasal corticosteroid + oral antihistamine as initial therapy; monotherapy is equally effective and more cost‑effective. Evidence from comparative trials. 2
Cetirizine and intranasal azelastine may cause sedation at recommended doses, unlike other second‑generation antihistamines (fexofenadine, loratadine, desloratadine). Safety profile data. 1

The American Academy of Allergy, Asthma, and Immunology recommends intranasal corticosteroids as the most effective medication class for controlling allergic rhinitis symptoms, including sneezing, itching, rhinorrhea, and nasal congestion, in children 7, 8
For a child aged 2-5 years, triamcinolone acetonide (Nasacort Allergy 24HR) is recommended at a dosage of 1 spray per nostril once daily, as it is FDA-approved for children ≥2 years of age 8
Mometasone furoate (Nasonex) is another option approved for children as young as 2 years at a dosage of 1 spray per nostril daily 8
Fluticasone propionate (Flonase) is only FDA-approved for children ≥4 years at a dosage of 1 spray per nostril daily 8

If intranasal corticosteroids are not tolerated, second-generation oral antihistamines may be considered for symptoms of sneezing and itching, as recommended by the American Academy of Allergy, Asthma, and Immunology 7, 8
Second-generation antihistamines (cetirizine, loratadine, fexofenadine) are preferred over first-generation antihistamines due to less sedation and fewer anticholinergic effects 9
Intranasal cromolyn sodium is another option with a strong safety profile, though it is less effective than intranasal corticosteroids 8
Leukotriene receptor antagonists (montelukast) are not recommended as primary therapy for allergic rhinitis in children, according to the American College of Physicians 10, 8

Allergen avoidance is fundamental to successful management of allergic rhinitis, as stated by the American Academy of Allergy, Asthma, and Immunology 11
Identify and educate the patient's caregivers about avoiding specific triggers, as recommended by the American Academy of Allergy, Asthma, and Immunology 11
Consider the presence of comorbid conditions such as asthma, eczema, or allergic conjunctivitis, which frequently occur with allergic rhinitis, according to the American Academy of Otolaryngology-Head and Neck Surgery 12

Avoid oral decongestants in young children as they can cause irritability, insomnia, and loss of appetite, as warned by the American Academy of Allergy, Asthma, and Immunology 9
Topical decongestants should only be used short-term (less than 3 days) to avoid rhinitis medicamentosa, as cautioned by the American Academy of Allergy, Asthma, and Immunology 7
First-generation antihistamines should be avoided due to their sedative and anticholinergic effects, as recommended by the American Academy of Allergy, Asthma, and Immunology 9
Systemic corticosteroids should be reserved for severe, intractable symptoms and used only for short courses, as advised by the American Academy of Allergy, Asthma, and Immunology 11